The Treatment of Experimental Lymphedema

Földi-Börcsök, Ethel; Casley‐Smith, J. R.; Foldi, M

doi:10.1159/000157921

Cited by 6 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The 66-94% mean reduction of oedema in the study indicates a comparable result with the other multiple encasing devices for lower extremity lymphoedema management [1,23]. Using high pressure helped us to obtain acceptable responses, which is due to some degrees of fi brosis in most of our patients.…”

Section: Discussionsupporting

confidence: 62%

A newly designed SIPC device for management of lymphoedema

Modaghegh

Soltani

2010

Indian J Surg

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 62%

A newly designed SIPC device for management of lymphoedema

Modaghegh

Soltani

2010

Indian J Surg

View full text Add to dashboard Cite

show abstract

“…Coumarin has been used since the 1970s for the treatment of various pathologies, including lymphoedema, varicose veins, lung and kidney carcinoma, melanoma, infections, and chronic fatigue syndrome [100][101][102][103][104][105][106][107]. Thus, thousands of individuals have been exposed to therapeutic doses of coumarin for periods ranging from 2 weeks to over 2 years.…”

Section: Clinical Trialsmentioning

confidence: 99%

Coumarin-Induced Hepatotoxicity: A Narrative Review

et al. 2022

View full text Add to dashboard Cite

Coumarin is an effective treatment for primary lymphoedema, as well as lymphoedema related to breast cancer radiotherapy or surgery. However, its clinical use is limited in several countries due to the possible occurrence of hepatotoxicity, mainly in the form of mild to moderate transaminase elevation. It is worth noting that only a few cases of severe hepatotoxicity have been described in the literature, with no reported cases of liver failure. Data available on coumarin absorption, distribution, metabolism, and excretion have been reviewed, focusing on hepatotoxicity studies carried out in vitro and in vivo. Finally, safety and tolerability data from clinical trials have been thoroughly discussed. Based on these data, coumarin-induced hepatotoxicity is restricted to a small subset of patients, probably due to the activation in these individuals of alternative metabolic pathways involving specific CYP450s isoforms. The aim of this work is to stimulate research to clearly identify patients at risk of developing hepatotoxicity following coumarin treatment. Early identification of this subset of patients could open the possibility of more safely exploiting the therapeutical properties of coumarin, allowing patients suffering from lymphoedema to benefit from the anti-oedematous activity of the treatment.

show abstract

“…Coumarin has been used since the seventies for the treatment of various pathologies including lymphoedema, varicose veins, lung and kidney carcinoma, melanoma, infections and chronic fatigue syndrome [97][98][99][100][101][102][103][104]. Thus, thousands of individuals have been exposed to therapeutic doses of coumarin for periods ranging from 2 weeks to over 2 years.…”

Section: Clinical Trialsmentioning

confidence: 99%

Coumarin-induced Hepatotoxicity: A Narrative Review

Pitaro¹,

Croce²,

Gallo³

et al. 2022

Preprint

View full text Add to dashboard Cite

Coumarin is an effective treatment for primary lymphoedema, as well as lymphoedema related to breast cancer radiotherapy or surgery. However, its clinical use is limited in several countries due to the possible occurrence of hepatotoxicity, mainly in the form of mild to moderate transaminase elevation. Noteworthy, only few cases of severe hepatotoxicity have been described in literature, with no reported cases of liver failure. Data available on coumarin absorption, distribution, metabolism and excretion have been reviewed, focusing on hepatotoxicity studies carried out in vitro and in vivo. Finally, safety and tolerability data from clinical trials have been thoroughly discussed. On the basis of these data, coumarin-induced hepatotoxicity seems to be restricted to a small subset of patients, probably due to the expression of specific alleles of CYP450 isoform not yet well characterized. In summary, more research is needed in order to identify patients at risk of developing hepatotoxicity following coumarin treatment, in order to improve the risk/benefit ratio of the product and allow more patients to benefit from its therapeutic properties.

show abstract

The Treatment of Experimental Lymphedema

Abstract: It has been shown previously, by plethysmographic measurements, that experimental lymphedema can be treated successfully by administration of coumarin and by massage. The present study confirms this fact by histological examination.

Cited by 6 publications

References 0 publications

A newly designed SIPC device for management of lymphoedema

A newly designed SIPC device for management of lymphoedema

Coumarin-Induced Hepatotoxicity: A Narrative Review

Coumarin-induced Hepatotoxicity: A Narrative Review

Contact Info

Product

Resources

About